NCT00719511

Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration

Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind, Dose-response Study to Assess the Optimal Dose as Well as Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 132 (estimated)
• Sponsor: University of Zurich · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of patch as specific immunotherapy in allergic patients

Conditions

• Allergies

Interventions

Type	Name	Description
DRUG	Purified allergen dose 1 integrated in a Patch system	Epicutaneous application of a patch
DRUG	Purified allergen dose 2 integrated in a Patch system	Epicutaneous application of a patch
DRUG	Purified allergen dose 3 integrated in a Patch system	Epicutaneous application of a patch
DRUG	Purified allergen integrated in a Patch system	Epicutaneous application of a patch

Timeline

• Start date: 2008-02-01
• Primary completion: 2009-11-01
• Completion: 2009-12-01
• First posted: 2008-07-21
• Last updated: 2011-02-17

Locations

1 site across 1 country: Switzerland